Covid-19; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Covid-19) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039D21A, 013F20A and 031F20A) for COVID-19 vaccination.     Concurrent medical conditions included Autonomic dysfunction (autonomic syndrome), Osteoporosis, Scoliosis, Mitral valve prolapse, Spinal stenosis, Postural orthostatic tachycardia syndrome (Possible POTS) and Sulfonamide allergy (Sulfa drugs). Concomitant products included AZITHROMYCIN (ZITHROMAX Z-PACK) from 24-May-2022 to 28-May-2022, IBUPROFEN (ADVIL [IBUPROFEN]) from 23-May-2022 to 26-May-2022, GUAIFENESIN (MUCINEX) from 23-May-2022 to 26-May-2022 and VITAMINS NOS for an unknown indication.   On 16-Jan-2021 at 11:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Feb-2021 at 11:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Oct-2021 at 3:00 AM, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (Covid-19). At the time of the report, COVID-19 (Covid-19) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Further Concurrent condition reported.  It was reported that the patient taken other medications/products within 2 weeks of starting COVID-19 treatment.  Patient had Covid Rebound on 03-jun-2022 at 05:00 PM with outcone Not Recovered Not Resolved. The Rebound Covid  treated by Nebulizer, Advil, Mucinex, Nasal Saline Device on 06-Jun-2022.  Patient took unknown Pfizer substance for Covid -19 treatment from 25-May-2022 to 29-May-2022.  Company Comment:This spontaneous case concerns a 68-year-old, female patient with no relevant medical history who experienced the unexpected, non-serious adverse event of special interest of COVID-19 which occurred on unspecified interval after receiving the third dose of mRNA-1273 vaccine. Patient has completed the primary series of vaccination with mRNA-1273 taken within the recommended dosing interval approximately 8 months prior to the current dose. Patient was diagnosed to have COVID-19 and was treated with 5-day course of unspecified COVID-19 treatment.  Azithromycin, Ibuprofen, Guaifenesin, Saline nasal spray and nebulization were also given. Rebound of COVID-19 symptoms was reported but the clinical course was not provided. At the time of report, the event has not resolved. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a 68-year-old, female patient with no relevant medical history who experienced the unexpected, non-serious adverse event of special interest of COVID-19 which occurred on unspecified interval after receiving the third dose of mRNA-1273 vaccine. Patient has completed the primary series of vaccination with mRNA-1273 taken within the recommended dosing interval approximately 8 months prior to the current dose. Patient was diagnosed to have COVID-19 and was treated with 5-day course of unspecified COVID-19 treatment.  Azithromycin, Ibuprofen, Guaifenesin, Saline nasal spray and nebulization were also given. Rebound of COVID-19 symptoms was reported but the clinical course was not provided. At the time of report, the event has not resolved. The benefit-risk relationship of mRNA-1273 is not affected by this report.